{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:21:46Z","timestamp":1792657306630,"version":"4.5.0"},"reference-count":29,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>We aimed to identify doses of mirogabalin (DS-5565) providing clinically meaningful efficacy with manageable side effects for treatment of diabetic peripheral neuropathic pain (DPNP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Adults (\u226518 years) with type 1 or 2 diabetes, HbA1c \u226410% at screening, and DPNP for \u22656 months were eligible for study participation. Subjects (n = 452) were randomized (2:1:1:1:1:1:1 ratio) to placebo, dose-ranging mirogabalin (5, 10, 15, 20, and 30 mg\/day), or pregabalin (300 mg\/day) for 5 weeks. The primary end point was weekly change in average daily pain score (ADPS; 0 to 10 numeric rating scale) from baseline to week 5 (minimally meaningful effect, \u22651.0-point decrease versus placebo). ANCOVA was conducted using last observation carried forward, and treatment effect least squares (LS) means were provided for each contrast. Safety assessments included adverse events (AEs), clinical laboratory tests, and electrocardiograms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>LS mean differences in change in ADPS from baseline to week 5 versus placebo were \u20130.22, \u20130.53, \u20130.94, \u20130.88, and \u20131.01 for the mirogabalin 5-, 10-, 15-, 20-, and 30-mg\/day treatment groups, respectively, and \u20130.05 in the pregabalin group (P &amp;lt; 0.05 versus placebo for mirogabalin 15, 20, and 30 mg\/day). Most frequent AEs (n = 277) were primarily mild to moderate dizziness (9.4%), somnolence (6.1%), and headache (6.1%); otherwise, mirogabalin was well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Mirogabalin 15, 20, and 30 mg\/day had statistically significant reductions in ADPS versus placebo, and mirogabalin 30 mg\/day also met the criteria of minimally meaningful effect. Mirogabalin may be a promising new treatment option for patients with DPNP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc14-1044","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T07:21:46Z","timestamp":1411024906000},"page":"3253-3261","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":95,"title":["Efficacy and Safety of Mirogabalin (DS-5565) for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo- and Active Comparator\u2013Controlled, Adaptive Proof-of-Concept Phase 2 Study"],"prefix":"10.2337","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01496365","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Aaron","family":"Vinik","sequence":"first","affiliation":[{"name":"Eastern Virginia Medical School, Norfolk, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sharma","sequence":"additional","affiliation":[{"name":"MMS Holdings Inc., Canton, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Feins","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development, Edison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching","family":"Hsu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development, Edison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Merante","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Development, Gerrards Cross, Buckinghamshire, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"2022031219322702100_B1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1526-4637.2007.00347.x","article-title":"Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options","volume":"9","author":"Veves","year":"2008","journal-title":"Pain Med"},{"key":"2022031219322702100_B2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ecl.2013.06.001","article-title":"Diabetic neuropathy","volume":"42","author":"Vinik","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022031219322702100_B3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pain.2010.02.034","article-title":"The burden of neuropathic pain: a systematic review and meta-analysis of health utilities","volume":"149","author":"Doth","year":"2010","journal-title":"Pain"},{"key":"2022031219322702100_B4","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2337\/dc12-1964","article-title":"Mechanisms and management of diabetic painful distal symmetrical polyneuropathy","volume":"36","author":"Tesfaye","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031219322702100_B5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/dmrr.2239","article-title":"Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy","volume":"28","author":"Tesfaye","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031219322702100_B6","doi-asserted-by":"crossref","first-page":"a003947","DOI":"10.1101\/cshperspect.a003947","article-title":"Voltage-gated calcium channels","volume":"3","author":"Catterall","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2022031219322702100_B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","article-title":"Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation","volume":"125","author":"Li","year":"2006","journal-title":"Pain"},{"key":"2022031219322702100_B8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","article-title":"Mechanisms of analgesia by gabapentin and pregabalin\u2014calcium channel alpha2-delta [Cavalpha2-delta] ligands","volume":"142","author":"Taylor","year":"2009","journal-title":"Pain"},{"key":"2022031219322702100_B9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/jm060650z","article-title":"Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain","volume":"50","author":"Field","year":"2007","journal-title":"J Med Chem"},{"key":"2022031219322702100_B10"},{"key":"2022031219322702100_B11","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","article-title":"Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin","volume":"103","author":"Field","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031219322702100_B12","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1523\/JNEUROSCI.21-16-06095.2001","article-title":"Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells","volume":"21","author":"Barclay","year":"2001","journal-title":"J Neurosci"},{"key":"2022031219322702100_B13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","article-title":"Pregabalin is a potent and selective ligand for \u03b1(2)\u03b4-1 and \u03b1(2)\u03b4-2 calcium channel subunits","volume":"667","author":"Li","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"2022031219322702100_B14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/dmrr.1225","article-title":"Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management","volume":"27","author":"Tesfaye","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031219322702100_B15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mus.22092","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy\u2014report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation","volume":"43","author":"Bril","year":"2011","journal-title":"Muscle Nerve"},{"key":"2022031219322702100_B16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/DMSO.S24825","article-title":"Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin","volume":"6","author":"Vinik","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031219322702100_B17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0025-6196(11)61474-2","article-title":"Diabetic peripheral neuropathic pain: clinical and quality-of-life issues","volume":"81","author":"Argoff","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2022031219322702100_B18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pain.2009.02.007","article-title":"Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2)","volume":"144","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"2022031219322702100_B19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc07-2105","article-title":"Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses","volume":"31","author":"Freeman","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219322702100_B20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"2022031219322702100_B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"2022031219322702100_B22","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1097\/00002508-200006001-00018","article-title":"What is clinically meaningful: outcome measures in pain clinical trials","volume":"16","author":"Farrar","year":"2000","journal-title":"Clin J Pain"},{"key":"2022031219322702100_B23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","article-title":"Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study","volume":"12","author":"T\u00f6lle","year":"2008","journal-title":"Eur J Pain"},{"key":"2022031219322702100_B24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain"},{"key":"2022031219322702100_B25","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"2022031219322702100_B26","unstructured":"European Medicines Agency. Lyrica scientific discussion [article online], 2014. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000546\/WC500046600.pdf. Accessed 6 February 2014"},{"key":"2022031219322702100_B27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pme.12310","article-title":"Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia","volume":"15","author":"Vinik","year":"2014","journal-title":"Pain Med"},{"key":"2022031219322702100_B28","article-title":"Developing new molecules for the treatment of painful diabetic peripheral neuropathy: Is it feasible given the magnitude of the placebo response in proof of concept clinical studies?","author":"Merante","year":"2013","journal-title":"J Diabetes Metab"},{"key":"2022031219322702100_B29"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3253\/619694\/3253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3253\/619694\/3253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:09:14Z","timestamp":1647119354000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/12\/3253\/29308\/Efficacy-and-Safety-of-Mirogabalin-DS-5565-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,8]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,8]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-1044","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,8]]}}}